Eli Lilly surged the most since 2008 after a positive study for its drug combo in patients with a type of breast cancer was heralded by analysts as a transformational event, especially in the wake of Pfizer’s failure earlier this month $LLY $PFE

https://t.co/qw4mW21gJl